抽象的
在严重的慢性哮喘中,可能需要长期口服类固醇来控制症状。在正在考虑此类治疗的患者中,Salmeterol Xinafoate 100微克B.I.D.的疗效和安全性在一项随机,双盲,安慰剂对照的平行组,多中心研究中进行了研究。将一百十九个慢性症状性哮喘患者随机分配,以接收Salmeterol,100微克B.I.D.(n = 55;基线%预测早晨峰值呼气流量(PEF)59%;一秒钟(FEV1)66%的强迫呼气量)或安慰剂(n = 64;基线%;基线%预测早晨PEF 63%; FEV1 66%)都通过磁盘。早晨和晚上的PEF和哮喘症状记录在每日记录的小册子中,在12周的时间内。Salmeterol治疗组1个月后,早晨PEF取得了显着改善;这在整个治疗期间持续存在(估计的治疗差22 L.min-1)。与安慰剂(13(26)%)相比,Salmeterol治疗组所经历的无症状夜晚比例显着增加,每天使用救济药物的使用显着减少(平均值) decrease 5.1 (4.7) doses per day with salmeterol, 2.5 (4.0) doses with placebo). Both treatments were well-tolerated, with no evidence of any difference in the side-effects associated with beta 2-agonists. In conclusion, the addition of salmeterol (100 micrograms daily) to the existing treatment of chronic asthmatics under consideration for maintenance oral corticosteroid therapy is well-tolerated, improves lung function and provides additional symptom control.